Advanced

Tumor markers in prostate cancer I: Blood-based markers

Shariat, Shahrokh F.; Semjonow, Axel; Lilja, Hans LU ; Savage, Caroline; Vickers, Andrew J. and Bjartell, Anders LU (2011) In Acta Oncologica 50. p.61-75
Abstract
The introduction of total prostate specific antigen (total PSA) testing in blood has revolutionized the detection and management of men with prostate cancer (PCa). The objective of this review was to discuss the challenges of PCa biomarker research, definition of the type of PCa biomarkers, the statistical considerations for biomarker discovery and validation, and to review the literature regarding total PSA velocity and novel blood-based biomarkers. Methods. An English-language literature review of the Medline database (1990 to August 2010) of published data on blood-based biomarkers and PCa was undertaken. Results. The inherent biological variability of total PSA levels affects the interpretation of any single result. Men who will... (More)
The introduction of total prostate specific antigen (total PSA) testing in blood has revolutionized the detection and management of men with prostate cancer (PCa). The objective of this review was to discuss the challenges of PCa biomarker research, definition of the type of PCa biomarkers, the statistical considerations for biomarker discovery and validation, and to review the literature regarding total PSA velocity and novel blood-based biomarkers. Methods. An English-language literature review of the Medline database (1990 to August 2010) of published data on blood-based biomarkers and PCa was undertaken. Results. The inherent biological variability of total PSA levels affects the interpretation of any single result. Men who will eventually develop PCa have increased total PSA levels years or decades before the cancer is diagnosed. Total PSA velocity improves predictiveness of total PSA only marginally, limiting its value for PCa screening and prognostication. The combination of PSA molecular forms and other biomarkers improve PCa detection substantially. Several novel blood-based biomarkers such as human glandular kallikrein 2 (hK2), urokinase plasminogen activator (uPA) and its receptor (uPAR), transforming growth factor-beta 1 (TGF-beta 1); interleukin-6 (IL-6) and its receptor (IL-6R) may help PCa diagnosis, staging, prognostication, and monitoring. Panels of biomarkers that capture the biologic potential of PCa are in the process of being validated for PCa prognostication. Conclusions. PSA is a strong prognostic marker for long-term risk of clinically relevant cancer. However, there is a need for novel biomarkers that aid clinical decision making about biopsy and initial treatment. There is no doubt that progress will continue based on the integrated collaboration of researchers, clinicians and biomedical firms. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Acta Oncologica
volume
50
pages
61 - 75
publisher
Taylor & Francis
external identifiers
  • wos:000290871000012
  • scopus:79957461212
ISSN
1651-226X
DOI
10.3109/0284186X.2010.542174
language
English
LU publication?
yes
id
2e3e4666-5ee4-46dd-b1aa-b37e72d5efe4 (old id 1986588)
date added to LUP
2011-07-01 09:15:16
date last changed
2017-11-19 03:55:04
@article{2e3e4666-5ee4-46dd-b1aa-b37e72d5efe4,
  abstract     = {The introduction of total prostate specific antigen (total PSA) testing in blood has revolutionized the detection and management of men with prostate cancer (PCa). The objective of this review was to discuss the challenges of PCa biomarker research, definition of the type of PCa biomarkers, the statistical considerations for biomarker discovery and validation, and to review the literature regarding total PSA velocity and novel blood-based biomarkers. Methods. An English-language literature review of the Medline database (1990 to August 2010) of published data on blood-based biomarkers and PCa was undertaken. Results. The inherent biological variability of total PSA levels affects the interpretation of any single result. Men who will eventually develop PCa have increased total PSA levels years or decades before the cancer is diagnosed. Total PSA velocity improves predictiveness of total PSA only marginally, limiting its value for PCa screening and prognostication. The combination of PSA molecular forms and other biomarkers improve PCa detection substantially. Several novel blood-based biomarkers such as human glandular kallikrein 2 (hK2), urokinase plasminogen activator (uPA) and its receptor (uPAR), transforming growth factor-beta 1 (TGF-beta 1); interleukin-6 (IL-6) and its receptor (IL-6R) may help PCa diagnosis, staging, prognostication, and monitoring. Panels of biomarkers that capture the biologic potential of PCa are in the process of being validated for PCa prognostication. Conclusions. PSA is a strong prognostic marker for long-term risk of clinically relevant cancer. However, there is a need for novel biomarkers that aid clinical decision making about biopsy and initial treatment. There is no doubt that progress will continue based on the integrated collaboration of researchers, clinicians and biomedical firms.},
  author       = {Shariat, Shahrokh F. and Semjonow, Axel and Lilja, Hans and Savage, Caroline and Vickers, Andrew J. and Bjartell, Anders},
  issn         = {1651-226X},
  language     = {eng},
  pages        = {61--75},
  publisher    = {Taylor & Francis},
  series       = {Acta Oncologica},
  title        = {Tumor markers in prostate cancer I: Blood-based markers},
  url          = {http://dx.doi.org/10.3109/0284186X.2010.542174},
  volume       = {50},
  year         = {2011},
}